A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma

A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 243(2022) vom: 11. Okt., Seite 109105
1. Verfasser: Wang, Xiaoxuan (VerfasserIn)
Weitere Verfasser: Hong, Yuheng, Meng, Shen, Gong, Wenchen, Ren, Tianyuan, Zhang, Tingting, Liu, Xianming, Li, Lanfang, Qiu, Lihua, Qian, Zhengzi, Zhou, Shiyong, Zhao, Mengmeng, Zhai, Qiongli, Meng, Bin, Ren, Xiubao, Zhang, Huilai, Wang, Xianhuo
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't DLBCL Epigenetic signature Immune infiltration Prognosis Response Antibodies, Monoclonal, Murine-Derived Cytokines Myeloid Differentiation Factor 88 mehr... Cytarabine 04079A1RDZ Rituximab 4F4X42SYQ6 Vorinostat 58IFB293JI Vincristine 5J49Q6B70F Doxorubicin 80168379AG Cyclophosphamide 8N3DW7272P Histone Methyltransferases EC 2.1.1.- Protein Methyltransferases Prednisone VB0R961HZT
LEADER 01000naa a22002652 4500
001 NLM345728041
003 DE-627
005 20231226025731.0
007 cr uuu---uuuuu
008 231226s2022 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2022.109105  |2 doi 
028 5 2 |a pubmed24n1152.xml 
035 |a (DE-627)NLM345728041 
035 |a (NLM)36055572 
035 |a (PII)S1521-6616(22)00186-3 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Wang, Xiaoxuan  |e verfasserin  |4 aut 
245 1 2 |a A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma 
264 1 |c 2022 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 20.09.2022 
500 |a Date Revised 22.12.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved. 
520 |a Epigenetic modifications contribute to lymphomagenesis. Here, we performed an expression clustering analysis and identified two epigenetic-related clusters (EC1 and EC2). EC1 presented abundant TP53, MYD88, HIST1H1D, HIST1H1C, KMT2D and EZH2 mutations and an inferior prognosis. Pathways involved in the regulation of DNA methylation/demethylation, histone methyltransferase activity, and protein methyltransferase activity were significantly enriched in EC1. However, EC2 was frequently accompanied by B2M, CD70 and MEF2B mutations, which presented with enrichments in DNA damage repair, cytokine-mediated and B-cell activated immune signaling, increased levels of CD8+ T-, γδT- and T helper-cells, as well as immune scores and immunogenic cell death (ICD) modulators. According to the prediction, EC1 was more sensitive to vorinostat, serdemetan and navitoclax. However, ruxolitinib, cytarabine and CP466722 were more suitable treatments for EC2. The novel immune-related epigenetic signature exhibits promising clinical predictive value for diffuse large B-cell lymphoma (DLBCL), particularly for guiding epigenetic therapeutic regimens. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) based combination treatment regimens are suggested 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a DLBCL 
650 4 |a Epigenetic signature 
650 4 |a Immune infiltration 
650 4 |a Prognosis 
650 4 |a Response 
650 7 |a Antibodies, Monoclonal, Murine-Derived  |2 NLM 
650 7 |a Cytokines  |2 NLM 
650 7 |a Myeloid Differentiation Factor 88  |2 NLM 
650 7 |a Cytarabine  |2 NLM 
650 7 |a 04079A1RDZ  |2 NLM 
650 7 |a Rituximab  |2 NLM 
650 7 |a 4F4X42SYQ6  |2 NLM 
650 7 |a Vorinostat  |2 NLM 
650 7 |a 58IFB293JI  |2 NLM 
650 7 |a Vincristine  |2 NLM 
650 7 |a 5J49Q6B70F  |2 NLM 
650 7 |a Doxorubicin  |2 NLM 
650 7 |a 80168379AG  |2 NLM 
650 7 |a Cyclophosphamide  |2 NLM 
650 7 |a 8N3DW7272P  |2 NLM 
650 7 |a Histone Methyltransferases  |2 NLM 
650 7 |a EC 2.1.1.-  |2 NLM 
650 7 |a Protein Methyltransferases  |2 NLM 
650 7 |a EC 2.1.1.-  |2 NLM 
650 7 |a Prednisone  |2 NLM 
650 7 |a VB0R961HZT  |2 NLM 
700 1 |a Hong, Yuheng  |e verfasserin  |4 aut 
700 1 |a Meng, Shen  |e verfasserin  |4 aut 
700 1 |a Gong, Wenchen  |e verfasserin  |4 aut 
700 1 |a Ren, Tianyuan  |e verfasserin  |4 aut 
700 1 |a Zhang, Tingting  |e verfasserin  |4 aut 
700 1 |a Liu, Xianming  |e verfasserin  |4 aut 
700 1 |a Li, Lanfang  |e verfasserin  |4 aut 
700 1 |a Qiu, Lihua  |e verfasserin  |4 aut 
700 1 |a Qian, Zhengzi  |e verfasserin  |4 aut 
700 1 |a Zhou, Shiyong  |e verfasserin  |4 aut 
700 1 |a Zhao, Mengmeng  |e verfasserin  |4 aut 
700 1 |a Zhai, Qiongli  |e verfasserin  |4 aut 
700 1 |a Meng, Bin  |e verfasserin  |4 aut 
700 1 |a Ren, Xiubao  |e verfasserin  |4 aut 
700 1 |a Zhang, Huilai  |e verfasserin  |4 aut 
700 1 |a Wang, Xianhuo  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 243(2022) vom: 11. Okt., Seite 109105  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:243  |g year:2022  |g day:11  |g month:10  |g pages:109105 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2022.109105  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 243  |j 2022  |b 11  |c 10  |h 109105